oral plasmodium eEF2 inhibitor
Ph. I candidate for malaria treatment
from phenotypic screen & optimization
The Lancet
Merck Institute for Pharmacometrics
M5717
13. The Merck Institute antimalarial compound, M5717, is the first plasmodium eEF2 inhibitor to reach clinical development, and is a good example of an orally available dibasic compound as well…